FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2127-2137 May 15, 2008 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Tuhrim, S. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes.

Methods We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 µg of rFVIIa per kilogram of body weight (276 patients), or 80 µg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke.

Results Treatment with 80 µg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 µg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 µg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], –0.3 to 5.5; P=0.08) in the group receiving 20 µg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 µg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 µg of rFVIIa per kilogram, and 29% in the group receiving 80 µg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 µg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04).

Conclusions Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov] .)

Source Information

From the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons, New York (S.A.M.); Novo Nordisk, Bagsvaerd, Denmark (N.C.B., K.B.); the University of Cincinnati Medical Center, Cincinnati (J.B.); the Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia (S.D.); Washington University School of Medicine, St. Louis (M.N.D.); Novo Nordisk, Princeton, NJ (B.E.S.); and the University of Heidelberg, Heidelberg, Germany (T.S.).

Address reprint requests to Dr. Mayer at the Neurological Institute, 710 W. 168th St., Box 39, New York, NY 10032, or at sam14{at}columbia.edu.

Full Text of this Article

This article has been cited by other articles:

• Hemphill, J. C. III, Farrant, M., Neill, T. A. Jr (2009). Prospective validation of the ICH Score for 12-month functional outcome. Neurology 73: 1088-1094 [Abstract] [Full Text]  
• Dutton, R., Hauser, C., Boffard, K., Dimsitts, J., Bernard, G., Holcomb, J., Leppaniemi, A., Tortella, B., Bouillon, B., CONTROL Steering Committee, (2009). Scientific and logistical challenges in designing the CONTROL trial: recombinant factor VIIa in severe trauma patients with refractory bleeding. Clin Trials 6: 467-479 [Abstract]  
• Culley, C. M., Guttendorf, S., Coldren, M., Skledar, S. J., Gross, P. R., Spiro, R. M., Triulzi, D. J., Ragni, M. V. (2009). Coagulation factor VIIa (recombinant) in nonhemophilic patients requiring neurosurgery. Am J Health Syst Pharm 66: 1554-1559 [Abstract] [Full Text]  
• Delgado Almandoz, J. E., Yoo, A. J., Stone, M. J., Schaefer, P. W., Goldstein, J. N., Rosand, J., Oleinik, A., Lev, M. H., Gonzalez, R. G., Romero, J. M. (2009). Systematic Characterization of the Computed Tomography Angiography Spot Sign in Primary Intracerebral Hemorrhage Identifies Patients at Highest Risk for Hematoma Expansion: The Spot Sign Score. Stroke 40: 2994-3000 [Abstract] [Full Text]  
• Hoffman, M., Monroe, D. M. (2009). Tissue Factor in Brain Is Not Saturated With Factor VIIa: Implications for Factor VIIa Dosing in Intracerebral Hemorrhage. Stroke 40: 2882-2884 [Full Text]  
• Naidech, A. M., Jovanovic, B., Liebling, S., Garg, R. K., Bassin, S. L., Bendok, B. R., Bernstein, R. A., Alberts, M. J., Batjer, H. H. (2009). Reduced Platelet Activity Is Associated With Early Clot Growth and Worse 3-Month Outcome After Intracerebral Hemorrhage. Stroke 40: 2398-2401 [Abstract] [Full Text]  
• Oleinik, A., Romero, J. M., Schwab, K., Lev, M. H., Jhawar, N., Delgado Almandoz, J. E., Smith, E. E., Greenberg, S. M., Rosand, J., Goldstein, J. N. (2009). CT Angiography for Intracerebral Hemorrhage Does Not Increase Risk of Acute Nephropathy. Stroke 40: 2393-2397 [Abstract] [Full Text]  
• Fowler, R. A., Adhikari, N. K. J., Scales, D. C., Lee, W. L., Rubenfeld, G. D. (2009). Update in Critical Care 2008. Am. J. Respir. Crit. Care Med. 179: 743-758 [Full Text]  
• Mackman, N. (2009). The Role of Tissue Factor and Factor VIIa in Hemostasis. Anesth. Analg. 108: 1447-1452 [Abstract] [Full Text]  
• Christensen, M. C., Mayer, S., Ferran, J.-M. (2009). Quality of Life After Intracerebral Hemorrhage: Results of the Factor Seven for Acute Hemorrhagic Stroke (FAST) Trial. Stroke 40: 1677-1682 [Abstract] [Full Text]  
• Flaherty, M. L., Adeoye, O., Sekar, P., Haverbusch, M., Moomaw, C. J., Tao, H., Broderick, J. P., Woo, D. (2009). The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage. Stroke 40: 1738-1742 [Abstract] [Full Text]  
• Ederies, A., Demchuk, A., Chia, T., Gladstone, D. J., Dowlatshahi, D., BenDavit, G., Wong, K., Symons, S. P., Aviv, R. I. (2009). Postcontrast CT Extravasation Is Associated With Hematoma Expansion in CTA Spot Negative Patients. Stroke 40: 1672-1676 [Abstract] [Full Text]  
• Mayer, S. A., Schwab, S. (2009). Advances in Critical Care and Emergency Medicine. Stroke 40: e298-e300 [Full Text]  
• Broderick, J. P. (2009). Evidence against rapid reversal of antiplatelet medications in acute intracerebral hemorrhage. Neurology 72: 1376-1377 [Full Text]  
• Torbey, M. T. (2009). Intracerebral Hemorrhage: What's Next?. Stroke 40: 1539-1540 [Full Text]  
• Hanley, D. F. (2009). Intraventricular Hemorrhage: Severity Factor and Treatment Target in Spontaneous Intracerebral Hemorrhage. Stroke 40: 1533-1538 [Abstract] [Full Text]  
• Barras, C. D., Tress, B. M., Christensen, S., MacGregor, L., Collins, M., Desmond, P. M., Skolnick, B. E., Mayer, S. A., Broderick, J. P., Diringer, M. N., Steiner, T., Davis, S. M., for the Recombinant Activated Factor VII Intracere, (2009). Density and Shape as CT Predictors of Intracerebral Hemorrhage Growth. Stroke 40: 1325-1331 [Abstract] [Full Text]  
• Mayer, S. A., Davis, S. M., Skolnick, B. E., Brun, N. C., Begtrup, K., Broderick, J. P., Diringer, M. N., Steiner, T. (2009). Can a Subset of Intracerebral Hemorrhage Patients Benefit From Hemostatic Therapy With Recombinant Activated Factor VII?. Stroke 40: 833-840 [Abstract] [Full Text]  
• Fishman, P E, Drumheller, B C, Dubon, M E, Slesinger, T L (2008). Recombinant activated factor VII use in the emergency department. Emerg. Med. J. 25: 625-630 [Abstract] [Full Text]  
• Hardy, J.-F., Belisle, S., Van der Linden, P. (2008). Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients: A Review of 17 Randomized Controlled Trials. Ann. Thorac. Surg. 86: 1038-1048 [Abstract] [Full Text]  
• (2008). Acute Hemorrhagic Stroke: rFVIIa Is Not Effective. JWatch Emergency Med. 2008: 2-2 [Full Text]  
• Tuhrim, S. (2008). Intracerebral Hemorrhage -- Improving Outcome by Reducing Volume?. NEJM 358: 2174-2176 [Full Text]  
• (2008). Factor VIIa Not Effective for Intracerebral Hemorrhage. JWatch General 2008: 1-1 [Full Text]  
• (2008). Recombinant Factor VIIa Fails to Modify Outcomes After Intracerebral Hemorrhage. JWatch Oncology and Hematology 2008: 1-1 [Full Text]  
• Dentali, F., Crowther, M. A. (2008). Management of Excessive Anticoagulant Effect Due to Vitamin K Antagonists. ASH Education Book 2008: 266-270 [Abstract] [Full Text]